Harrow (HROW) Projected to Post Quarterly Earnings on Monday

Key Points

• Harrow (HROW) is set to report its Q2 2025 earnings on August 6th, with analysts anticipating an earnings per share (EPS) of $0.01 and revenues of $64.23 million.
• In its previous earnings report, Harrow missed expectations with a reported loss of $0.38 EPS and $47.83 million in revenue, falling short of the $57 million estimate.
• Despite recent struggles, Harrow has an average analyst rating of "Buy" with a consensus price target of $63.83, indicating positive sentiment among analysts.

Harrow (NASDAQ:HROW - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $64.23 million for the quarter. Harrow has set its FY 2025 guidance at EPS.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, analysts expect Harrow to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Harrow Stock Down 1.7%

Shares of NASDAQ HROW traded down $0.53 during mid-day trading on Friday, reaching $31.23. The company had a trading volume of 530,570 shares, compared to its average volume of 442,110. The firm has a 50 day simple moving average of $31.66 and a two-hundred day simple moving average of $28.84. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23. The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01. The stock has a market cap of $1.15 billion, a P/E ratio of -55.77 and a beta of 0.41.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald started coverage on Harrow in a report on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. BTIG Research initiated coverage on Harrow in a research report on Thursday, June 12th. They set a "buy" rating and a $62.00 target price on the stock. William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating for the company. Finally, HC Wainwright increased their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $63.83.

Institutional Investors Weigh In On Harrow

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio purchased a new stake in shares of Harrow in the first quarter valued at $149,000. Royal Bank of Canada boosted its stake in shares of Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company's stock worth $261,000 after purchasing an additional 4,967 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock worth $483,000 after buying an additional 790 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.